Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Sandra Moraña-Fernández und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Cardiology Research Unit, IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Comp…. Hauptthemen laut MEDLINE: Valsartan, Biphenyl Compounds, Aminobutyrates, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 110 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The promising results obtained in the PARADIGM-HF trial prompted the approval of sacubitril/valsartan (SAC/VAL) as a first-in-class treatment for heart failure with reduced ejection fraction (HFrEF) patients. The effect of SAC/VAL treatment was also studied in patients with heart failure with preserved ejection fraction (HFpEF) and, although improvements in New York Heart Association (NYHA) class, HF hospitalizations, and cardiovascular deaths were observed, these results were not so promising. However, the demand for HFpEF therapies led to the approval of SAC/VAL as an alternative treatment, although further studies are needed. We aimed to elucidate the effects of a 9-week SAC/VAL treatment in cardiac function and metabolism using a preclinical model of HFpEF, the Zucker Fatty and Spontaneously Hypertensive (ZSF1) rats. We found that SAC/VAL significantly improved diastolic function parameters and modulated respiratory quotient during exercise. Ex-vivo studies showed that SAC/VAL treatment significantly decreased heart, liver, spleen, and visceral fat weights; cardiac hypertrophy and percentage of fibrosis; lipid infiltration in liver and circulating levels of cholesterol and sodium. Moreover, SAC/VAL reduced glycerophospholipids, cholesterol, and cholesteryl esters while increasing triglyceride levels in cardiac tissue. In conclusion, SAC/VAL treatment improved diastolic and hepatic function, respiratory metabolism, reduced hypercholesterolemia and cardiac fibrosis and hypertrophy, and was able to modulate cardiac metabolic profile. Our findings might provide further insight into the therapeutic benefits of SAC/VAL treatment in obese patients with HFpEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular and Molecular Cardiology Research Unit, IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, Spain; Cardiology…
- Cellular and Molecular Cardiology Research Unit, IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, Spain; Universidad…
- Cellular and Molecular Cardiology Research Unit, IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, Spain; Centro de I…
- Physiology and Pharmacology of Chronic Diseases (FIFAEC), Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
- Cellular and Molecular Cardiology Research Unit, IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS), Santiago de Compostela, Spain; Clinical Bi…
- Cardiovascular R&D Centre - UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
Zitieren
APA
Moraña-Fernández, S., Vázquez-Abuín, X., Aragón-Herrera, A., Anido-Varela, L., García-Seara, J., Otero-García, Ó., Rodríguez-Penas, D., Campos-Toimil, M., Otero-Santiago, M., Rodrigues, A., Gonçalves, A., Pereira Morais, J., Alves, I. N., Sousa-Mendes, C., Falcão-Pires, I., González-Juanatey, J. R., Feijóo-Bandín, S., & Lago, F. (2024). Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116571
Vancouver
Moraña-Fernández S, Vázquez-Abuín X, Aragón-Herrera A, Anido-Varela L, García-Seara J, Otero-García Ó, et al. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116571
BibTeX
@article{MoraaFernndez2024,
author = {Moraña-Fernández, Sandra and Vázquez-Abuín, Xocas and Aragón-Herrera, Alana and Anido-Varela, Laura and García-Seara, Javier and Otero-García, Óscar and Rodríguez-Penas, Diego and Campos-Toimil, Manuel and Otero-Santiago, Manuel and Rodrigues, Alexandre and Gonçalves, Alexandre and Pereira Morais, Juliana and Alves, Inês N and Sousa-Mendes, Cláudia and Falcão-Pires, Inês and González-Juanatey, José Ramón and Feijóo-Bandín, Sandra and Lago, Francisca},
title = {Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116571}
}
EUVIMED